Combining an intranasal antihistamine with an intranasal corticosteroid for the treatment of allergic rhinitis (AR) may provide improved symptom relief over monotherapy treatment. GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate. The efficacy and safety of GSP301 were evaluated in a large, phase 3 seasonal AR (SAR) study.
Methods
In this double-blind, randomized, parallel-group study [NCT02631551] , patients (≥12 years) with SAR were equally randomized to twice-daily GSP301 (olopatadine 665 μg/mometasone 25 μg BID), olopatadine HCl (665 μg BID), mometasone furoate (25 μg BID), or placebo (BID) for 14 days. The primary efficacy endpoint was the mean change from baseline in AM and PM reflective Total Nasal Symptom Scores (rTNSS), analyzed using mixed-effect model repeated measures. Adverse events (AEs) were also assessed. P=0.004), but olopatadine monotherapy was not significant (-0.37 [-0.78, 0.04]; P=0.076). Additionally, the percentages of patients with treatment-emergent AEs were similar across treatment groups: 12.9%, 12.5%, 7.1%, and 9.4% in the GSP301, olopatadine, mometasone, and placebo groups, respectively.
Results

A
Conclusion
In this study, twice-daily GSP301 treatment provided significant and clinically meaningful improvements in SAR nasal symptoms versus placebo and was well tolerated.
STUDY DESIGN
 Randomized, double-blind, parallel-group study (NCT02631551) conducted in patients ≥12 years of age with SAR (≥2 years) during the Spring pollen season (eg, tree/grass)
Figure 1. Study Design Endpoints
 Primary: mean change from baseline to end of 14-day treatment in patient-reported AM and PM 12-hour rTNSS for  GSP301 versus placebo  GSP301 versus olopatadine and mometasone monotherapies  Olopatadine and mometasone monotherapies versus placebo  Additional: mean change from baseline to end of 14-day treatment in patient-reported AM and PM 12-hour iTNSS for the same treatment comparisons above; mean AM and PM individual nasal symptoms over 14-day treatment period for GSP301 versus placebo; and safety/AEs
Statistical Analyses
 Efficacy endpoints were analyzed via mixed-effect model repeated measures, with change from baseline as the dependent variable, treatment group and site as fixed effect, and adjusting for covariates (site, baseline score, and study day as the within-patient effect)  A difference of 0.23 units in TNSS was considered clinically meaningful (defined as the minimal clinically important difference) 1  To adjust for multiplicity, a gate-keeping strategy was used in which any treatment comparisons following one that did not reach significance (statistical significance, P<0.05) were also considered not significant, regardless of the P value obtained
RESULTS
Patients
 Efficacy analyses were based on the full analysis set (FAS), defined as all randomized patients who received ≥1 dose of study drug and completed ≥1 post-baseline primary efficacy assessment (n=1,170)  Safety assessments were based on the safety analysis set (SAS), which included all patients who received ≥1 dose of study drug (n=1,180)  At baseline, patients had moderate to severe symptoms, with mean rTNSS ranging from 10.1 to 10.3 and mean iTNSS ranging from 9.2 to 9.4 ( Full analysis set; GSP301 n=299; olopatadine n=294; mometasone n=294; placebo n=283. BID, twice-daily dosing; iTNSS, instantaneous Total Nasal Symptom Score; rTNSS, reflective Total Nasal Symptom Score; SD, standard deviation.
Efficacy
rTNSS
 GSP301 treatment demonstrated significant and clinically meaningful improvements from baseline to end of 14-day treatment versus placebo (P<0.001) and olopatadine (P=0.003; Table 2 )  A clinically meaningful numerical improvement that approached statistical significance was observed with GSP301 versus mometasone (P=0.059; Table 2 ); all further comparisons were considered not statistically significant per the gate-keeping analysis strategy, even though some comparisons reached P<0.05 (Table 2) iTNSS  Similar to the rTNSS results, GSP301 demonstrated significant and clinically meaningful improvements from baseline to end of 14-day treatment compared with placebo (P<0.001; Table 2 )  GSP301 treatment also demonstrated significant and clinically meaningful improvements versus both monotherapy components: olopatadine, P=0.005; mometasone, P=0.041 (Table 2)  GSP301 demonstrated significant improvements on rTNSS and iTNSS vs placebo on day 1 and each subsequent day up to day 14 (P<0.05, all) suggesting sustained symptom improvement (Figure 2 ; data for olopatadine and mometasone not shown)
Figure 2. LS Mean (95% CI) Change from Baseline in Average AM and PM rTNSS (A) and iTNSS (B) With GSP301 vs Placebo Over 14 Days of Treatment
GSP301, olopatadine 665 μg/mometasone 25 μg BID. *P<0.05 vs placebo. BID, twice-daily dosing; CI, confidence interval; LS, least squares; iTNSS, instantaneous Total Nasal Symptom Score; rTNSS, reflective Total Nasal Symptom Score.
